Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bhatnagar Tarun, Chaudhuri Sirshendu, Ponnaiah Manickam, Yadav Pragya D, Sabarinathan R, Sahay Rima R, Ahmed Faheem, Aswathy S, Bhardwaj Pankaj, Bilimale Anil, Kumar M Santhosh, Logaraj M, Narlawar Uday, Palanivel C, Patel Prakash, Rai Sanjay K, Saxena Vartika, Singh Arvind, Thangaraj Jeromie Wv, Agarwal Ashwini, Alvi Yasir, Amoghashree, Ashok P, Babu Dinesh, Bahurupi Yogesh, Bhalavi Sangita, Behera Priyamadhaba, Biswas Priyanka Pandit, Charan Jaykaran, Chauhan Nishant Kumar, Chetak K B, Dar Lalit, Das Ayan, Deepashree R, Dhar Minakshi, Dhodapkar Rahul, Dipu T S, Dudeja Mridu, Dudhmal Manisha, Gadepalli Ravisekhar, Garg Mahendra Kumar, Gayathri A V, Goel Akhil Dhanesh, Gowdappa H Basavana, Guleria Randeep, Gupta Manoj Kumar, Islam Farzana, Jain Mannu, Jain Vineet, Jawahar M Lanord Stanley, Joshi Rajendra, Kant Shashi, Kar Sitanshu Sekhar, Kalita Deepjyoti, Khapre Meenakshi, Khichar Satyendra, Kombade Sarika Prabhakar, Kohli Sunil, Kumar Abhinendra, Kumar Anil, Kumar Deepak, Kulirankal Kiran G, Leela K V, Majumdar Triparna, Mishra Baijayantimala, Misra Puneet, Misra Sanjeev, Mohapatra Prasanta Raghab, Murthy M Narayana, Nyayanit Dimpal A, Patel Manish, Pathania Monika, Patil Savita, Patro Binod Kumar, Jalandra Ramniwas, Rathod Pragati, Shah Naimesh, Shete Anita, Shukla Deepak, Shwethashree M, Sinha Smita, Sumana M N, Surana Ashish, Trikha Anjan, Tejashree A, Venkateshan Mahalingam, Vijaykrishnan G, Wadhava Sarita, Wig Naveet, Gupta Nivedita, Abraham Priya, Murhekar Manoj V
Аннотация
METHODS: We did a multi-centric, hospital-based, case-control study between May and July 2021. Cases were severe COVID-19 patients, and controls were COVID-19 negative individuals from 11 hospitals. Vaccine effectiveness (VE) was estimated for complete (2 doses ≥ 14 days) and partial (1 dose ≥ 21 days) vaccination; interval between two vaccine doses and vaccination against the Delta variant. We used the random effects logistic regression model to calculate the adjusted odds ratios (aOR) with a 95% confidence interval (CI) after adjusting for relevant known confounders.
RESULTS: We enrolled 1143 cases and 2541 control patients. The VE of complete vaccination was 85% (95% CI: 79-89%) with AZD1222/Covishield and 71% (95% CI: 57-81%) with BBV152/Covaxin. The VE was highest for 6-8 weeks between two doses of AZD1222/Covishield (94%, 95% CI: 86-97%) and BBV152/Covaxin (93%, 95% CI: 34-99%). The VE estimates were similar against the Delta strain and sub-lineages.
CONCLUSION: BBV152/Covaxin and AZD1222/Covishield were effective against severe COVID-19 among the Indian population during the period of dominance of the highly transmissible Delta variant in the second wave of the pandemic. An escalation of two-dose coverage with COVID-19 vaccines is critical to reduce severe COVID-19 and further mitigate the pandemic in the country.